Advance Agrolife Confirms No Deviation in IPO Fund Utilisation for Q4FY26
Advance Agrolife Limited submitted a regulatory filing to BSE and NSE confirming no deviation in the utilisation of IPO proceeds for the quarter ended March 31, 2026, as verified by CARE Ratings. The company utilised Rs. 125.05 crore out of the total Rs. 192.84 crore raised, with the unutilised Rs. 67.79 crore invested in fixed deposits. General Corporate Purposes were fully utilised during the quarter, while working capital funding remains ongoing as per schedule.
*this image is generated using AI for illustrative purposes only.
Advance Agrolife Limited has submitted a regulatory filing to BSE Limited and the National Stock Exchange of India Limited, confirming no deviation in the utilisation of proceeds raised through its Initial Public Offer (IPO) for the quarter ended March 31, 2026. The statement, submitted pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was enclosed with the Monitoring Agency Report issued by CARE Ratings Limited. The filing was signed by Nisha Gupta, Company Secretary and Compliance Officer, on May 08, 2026.
IPO and Issue Details
Advance Agrolife raised funds through a Public Issue–Initial Public Offer (IPO), with equity shares listed on BSE Limited and the National Stock Exchange of India Limited with effect from October 08, 2025. The issue period ran from September 30, 2025, to October 03, 2025. Key details of the issue and the monitoring report are presented below:
| Parameter: | Details |
|---|---|
| Name of Listed Entity: | Advance Agrolife Limited |
| Mode of Fund Raising: | Public Issue – Initial Public Offer (IPO) |
| Date of Raising Funds: | October 06, 2025 |
| Issue Size: | Rs. 192.84 crore (Fresh Issue) |
| Type of Securities: | Equity Shares |
| Report Filed for Quarter Ended: | March 31, 2026 |
| Monitoring Agency: | CARE Ratings Limited |
| Deviation / Variation in Use of Funds: | No |
| Comments of Audit Committee: | Nil |
| Comments of Auditors: | Nil |
Fund Utilisation Progress
CARE Ratings Limited confirmed that all utilisation is as per the disclosures in the Offer Document, with no material deviations from expenditures disclosed and no change in the means of finance towards the disclosed objects. The Chartered Accountant certificate was issued by S K Patodia & Associates LLP dated April 23, 2026. The following table details the progress in utilisation of IPO proceeds across all objects as at March 31, 2026:
| Sr. No. | Item Head | Amount Proposed (Rs. Crore) | Utilised at Beginning of Quarter (Rs. Crore) | Utilised During Quarter (Rs. Crore) | Utilised at End of Quarter (Rs. Crore) | Unutilised Amount (Rs. Crore) |
|---|---|---|---|---|---|---|
| 1. | Funding Working Capital Requirements | 135.00 | 67.50 | - | 67.50 | 67.50 |
| 2. | General Corporate Purposes (GCP) | 34.08 | 8.16 | 25.92 | 34.08 | - |
| 3. | Issue Related Expenses | 23.76 | 23.16 | 0.31 | 23.47 | 0.29 |
| Total | 192.84 | 98.82 | 26.23 | 125.05 | 67.79 |
No funds were utilised toward working capital requirements during Q4FY26, with Rs. 67.50 crore remaining unutilised under that head. Rs. 25.92 crore was utilised towards General Corporate Purposes (GCP) from the current account during Q4FY26, while Rs. 0.31 crore was spent from the public offer account towards issue-related expenses during the same period.
Deployment of Unutilised Proceeds
The total unutilised amount of Rs. 67.79 crore as on March 31, 2026, has been deployed as follows:
| Sr. No. | Instrument / Entity | Amount Invested (Rs. Crore) | Maturity Date | Earning (Rs. Crore) | Return on Investment (%) | Market Value at End of Quarter (Rs. Crore) |
|---|---|---|---|---|---|---|
| 1. | Fixed Deposit (Punjab National Bank) | 67.50 | 15-04-2026 | 1.66 | 6.03 | 69.16 |
| 2. | Monitoring Account (HDFC Bank) | 0.29 | - | - | - | - |
| Total | 67.79 |
General Corporate Purposes Utilisation
Of the Rs. 34.08 crore earmarked for General Corporate Purposes, the entire amount has been fully utilised as at the end of Q4FY26. The Rs. 25.92 crore deployed during Q4FY26 was directed towards capital expenditure, as per board resolution and confirmed by the Chartered Accountant certificate. As per the prospectus, the company had proposed to deploy the balance net proceeds aggregating to Rs. 34.08 crore towards general corporate purposes, subject to such utilisation not exceeding 25% of the Gross Proceeds of the Issue. The company obtained board approval on October 29, 2025, to utilise the GCP amount towards strategic initiatives, brand building, marketing and promotional activities, capital expenditure, and ongoing general corporate exigencies.
Implementation Timeline and Regulatory Context
The monitoring report also covers the implementation timeline for each object. Funding of working capital requirements is ongoing as per the offer document schedule of FY26 and FY27, with no delay reported. General corporate purposes were completed in FY26 as scheduled, and issue-related expenses remain ongoing with no delay. Under SEBI's Regulation 32, a material deviation is defined as a deviation in the objects or purposes for which funds were raised, or a deviation in the amount of funds actually utilised by more than 10% of the amount projected in the offer documents. CARE Ratings Limited confirmed no such deviations were observed. The filing was submitted on behalf of Advance Agrolife Limited (formerly known as Advance Agrolife Private Limited) by Nisha Gupta, Company Secretary and Compliance Officer, bearing Membership No. A42708.
Historical Stock Returns for Advance Agrolife
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.03% | +1.68% | +18.32% | -17.87% | +4.14% | +4.14% |
How will Advance Agrolife deploy the remaining Rs. 67.50 crore in working capital funds during FY27, and what operational expansion or seasonal demand cycles will drive that utilisation?
Given that the Fixed Deposit at Punjab National Bank matured on April 15, 2026, how has the company redeployed those funds, and will it maintain a conservative cash management strategy or accelerate working capital deployment?
How has the capital expenditure funded through General Corporate Purposes translated into tangible capacity additions or revenue growth since the IPO listing in October 2025?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
